Fig. 5: Sequential treatment of vincristine and S63845 stops tumor progression in the PDX model of RMS RMSX1. | Cell Death & Disease

Fig. 5: Sequential treatment of vincristine and S63845 stops tumor progression in the PDX model of RMS RMSX1.

From: Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance

Fig. 5: Sequential treatment of vincristine and S63845 stops tumor progression in the PDX model of RMS RMSX1.

a DBP results of PDX cells from RMS cancer patient showing an increase in ∆% priming after vincristine treatment. Results expressed as ∆% priming represents the increase in priming compared to control cells. n = 2. b DBP results of PDX cells from a RMS cancer patient with the sensitizer peptides. MS1 BH3 peptide showed a significant increase, indicating MCL-1 adaptation. n = 2. c Tumor growth results after 21 days of treatment with vehicle, vincristine, the BH3 mimetics S63845 and ABT-199 and the combination of vincristine and S63845. Day 0 indicates the day animals received the treatments. All values indicate mean values ± SEM. **p < 0.01, n = 3.

Back to article page